Essential Side Effect Differences: Making Your Choice
Wegovy vs Mounjaro Side Effects: UK Stock Availability Advantage
Understanding the side effect profiles of Wegovy versus Mounjaro becomes more relevant when both treatments are readily available for immediate prescription. Unlike periods of medication shortages, having consistent UK stock of both options allows you to choose based on clinical suitability rather than availability constraints. Wegovy (semaglutide) commonly causes nausea in approximately 44% of patients during clinical trials, whilst Mounjaro (tirzepatide) showed nausea rates of around 12-22% depending on the dose strength.
The timing and severity of side effects can influence treatment adherence, making stock availability crucial for maintaining consistent therapy. At EverydayMeds, our reliable supply chain from Novo Nordisk ensures all five Wegovy doses remain in stock, whilst our Mounjaro inventory covers the complete dose escalation range. This consistent availability means your prescriber can recommend dose adjustments or treatment switches based purely on your clinical response rather than supply limitations.
Wegovy vs Mounjaro Side Effects: Pricing and Value Considerations
The side effect profiles of Wegovy versus Mounjaro may influence your treatment duration and associated costs. Wegovy's starter dose costs £79.99 with new customer discount code FIRST40 applied at checkout, escalating to £209.99 for the 2.4mg maintenance dose. Our Intro Trio bundle (0.25mg, 0.5mg, and 1mg doses) provides the first 12 weeks of treatment for £299.99, helping you evaluate tolerability during the critical initial period.
Mounjaro's different side effect pattern may require alternative dosing strategies, potentially affecting long-term treatment costs. Our Getting Started bundles allow you to secure multiple dose strengths simultaneously, ensuring treatment continuity regardless of dose adjustments needed due to side effect management. Returning customers benefit from discount code DOSE25, making ongoing treatment more affordable as you progress through dose escalation phases.
Clinical Evidence: Wegovy vs Mounjaro Side Effects from Trials
The STEP trials revealed that patients taking Wegovy alongside diet and exercise experienced predominantly gastrointestinal side effects, with nausea being most common during the first 8-12 weeks of treatment. The SURPASS trials for Mounjaro demonstrated a different side effect pattern, with lower rates of nausea but similar rates of diarrhoea and vomiting across comparable patient populations.
Both medications showed that side effects typically diminish as patients adapt to treatment, though the timeline differs between Wegovy and Mounjaro based on their distinct mechanisms of action. These findings, published in peer-reviewed journals including Wilding et al., NEJM, 2021, help inform clinical decision-making when choosing between treatments based on individual patient factors and tolerability preferences.
How Wegovy Works: Side Effect Mechanism Understanding
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones to regulate appetite and gastric emptying. This mechanism directly explains why gastrointestinal side effects are most prominent, particularly during the dose escalation phases from 0.25mg to 2.4mg over 16 weeks. The medication slows gastric emptying, which promotes satiety but can initially cause nausea, particularly if you consume larger meals than your adjusted stomach capacity can comfortably handle. Understanding this mechanism helps patients adapt their eating patterns to minimise side effects whilst maximising therapeutic benefits. The majority of patients find that nausea subsides after 4-8 weeks as their digestive system adapts to the medication's effects on gastric motility.
Wegovy vs Mounjaro Side Effects: Ordering Process Considerations
Our streamlined 3-minute online clinical assessment specifically evaluates your medical history for factors that may predispose you to certain side effects with either Wegovy or Mounjaro. Following prescriber review (completed within 3 working days, or 24 hours with our express service), your medication ships via next-day cold-chain delivery to maintain optimal efficacy. This rapid turnaround time proves particularly valuable when switching between treatments due to side effect intolerance, as delays can disrupt your weight management progress. Our clinical team remains available throughout treatment to address side effect concerns and coordinate with your prescriber if dose adjustments become necessary. Having both medications consistently in stock means alternative treatment options remain readily accessible should your initial choice require modification.
Storage Requirements: Wegovy vs Mounjaro Side Effects During Travel
Both Wegovy and Mounjaro require refrigerated storage at 2-8°C before first use, but their room temperature tolerances differ significantly when considering travel or temporary storage situations. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This storage advantage may influence your choice if you frequently travel or lack consistent refrigeration access, as medication degradation could potentially alter side effect profiles or therapeutic effectiveness. The FlexTouch pen delivery system for Wegovy also provides consistent dosing accuracy, which helps maintain predictable side effect patterns throughout treatment. Proper storage ensures optimal medication potency, which directly correlates with expected side effect frequencies observed in clinical trials.
Unique Side Effect Patterns: Wegovy vs Mounjaro Comparison in UK Practice
Real-world UK prescription data suggests that patient tolerance patterns differ meaningfully between Wegovy and Mounjaro, influencing prescriber recommendations and patient satisfaction rates. Wegovy's side effects tend to be front-loaded during the initial dose escalation, with most patients experiencing peak nausea during weeks 5-8 when transitioning from 0.25mg to 0.5mg doses. Mounjaro users often report more gradual side effect onset with potentially better long-term tolerance, though individual responses vary significantly.
The availability of both treatments in UK stock allows for personalised treatment approaches based on lifestyle factors, work schedules, and social commitments that might be disrupted by different side effect timing patterns. Our clinical experience with UK patients suggests that having immediate access to alternative treatments improves overall satisfaction and treatment adherence when side effect management becomes challenging with the initial medication choice.
Final Treatment Decision: Wegovy vs Mounjaro Side Effects and Next Steps
Both Wegovy and Mounjaro represent evidence-based treatment options with distinct side effect profiles that may suit different patient preferences and medical circumstances. Your clinical assessment will help determine which medication's side effect pattern aligns better with your individual health profile and lifestyle requirements. New customers can begin with discount code FIRST40, whilst returning customers benefit from DOSE25 applied at checkout for ongoing treatment. Our GPhC-registered pharmacy (#9012878) ensures both medications remain consistently available for immediate dispatch following prescription approval. To start your personalised weight management journey with either Wegovy or Mounjaro, complete your clinical assessment at https://everydaymeds.co.uk/collections/wegovy where our prescribers can guide you through the most suitable treatment choice based on your individual circumstances and side effect considerations.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
